Article in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Ivan MaillardPerelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA.ORCID 0000-0003-1312-6748
Nathalie LabrecqueMaisonneuve-Rosemont Hospital Research Center, University of Montreal , Montreal, Canada.ORCID 0000-0001-7563-1542
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
HEMATOLOGY CLINICAL RESEARCH TRAINING PROGRAMT32HL007439 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE F BRASS, PETER S KLEIN · 1985 to 2026
$17.1M
Notch Signaling in AlloimmunityR01AI091627 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PEAR, WARREN S · 2011 to 2025
$6.0M
Immune System Development and RegulationT32AI055428 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ALLMAN, DAVID M, OLIVER, PAULA MARIA · 2003 to 2025
$4.2M
Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomasR01CA278976 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ivan Maillard, Ryan A Wilcox · 2024 to 2026
$1.9M
The role of secondary lymphoid organ fibroblastic cells in alloimmunityF30AI136315 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PERKEY, ERIC THOMAS · 2018 to 2021
$166k
American Society of Transplantation and Cellular TherapyCIHR PJT-152988Fonds de la Recherche Québec-SantéNational Institute for General Medical Sciences T32-GM007863National Institute of Allergy and Infectious Diseases R01-AI091627NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA278976NCI NIH HHS R01-CA278976NHLBI NIH HHS T32 HL007439NHLBI NIH HHS T32-HL07439NIAID NIH HHS F30 AI136315NIAID NIH HHS R01 AI091627NIAID NIH HHS T32 AI055428NIGMS NIH HHS T32 GM007863University of Montreal
6 · The paper itself
Abstract
A better understanding of the mechanisms regulating CD8+ T cell differentiation is essential to develop new strategies to fight infections and cancer. Using genetic mouse models and blocking antibodies, we uncovered cellular and molecular mechanisms by which Notch signaling favors the efficient generation of effector CD8+ T cells. Fibroblastic reticular cells from secondary lymphoid organs, but not dendritic cells, were the dominant source of Notch signals in T cells via Delta-like1/4 ligands within the first 3 days of immune responses to vaccination or infection. Using transcriptional and epigenetic studies, we identified a unique Notch-driven T cell-specific signature. Early Notch signals were associated with chromatin opening in regions occupied by bZIP transcription factors, specifically BATF, known to be important for CD8+ T cell differentiation. Overall, we show that fibroblastic reticular cell niches control the ultimate molecular and functional fate of CD8+ T cells after vaccination or infection through the delivery of early Notch signals.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Early Notch signals from fibroblastic reticular cells program effector CD8+ T cell differentiation. · full record | Socratic